Orlando, Fla.—Patients with the rare disease erythromelalgia who responded favorably to corticosteroid treatment have been found to have specific characteristics: They reached maximum pain intensity within 21 days of onset, described a clear trigger to their disease (typically surgery or trauma), and were treated more promptly with steroids after diagnosis.
The study’s principal investigator, Gabriel Pagani-Estévez, MD, a senior neurology resident at Mayo Clinic, in Rochester,